Apple's Strong Earnings Propel Stock Market Higher
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CAH?
Source: CNBC
- Apple's Earnings Surprise: Apple reported a projected revenue increase of 14% to 17% for the June quarter, significantly exceeding the Street's expectation of 9%, which solidifies its leadership position in the tech industry.
- Record Services Revenue: The company's services revenue reached an all-time high of $30.97 billion, up 16% year-over-year, indicating strong growth potential in its digital services segment and expected to drive future revenue growth.
- Positive Market Reaction: Apple's stock rose by 3.5%, with Wells Fargo raising its price target from $300 to $310, reflecting market optimism regarding its future performance.
- Memory Price Concerns: Despite Sandisk's earnings beating expectations, its shares fell 5%, highlighting market concerns over rising memory chip prices, which could impact overall industry profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 192.880
Low
209.00
Averages
225.18
High
244.00
Current: 192.880
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Reports Mixed Quarterly Results, Shares Decline
- Quarterly Revenue Growth: Cardinal Health reported an 11% year-over-year revenue increase to $60.94 billion for the quarter ending March 31, although it fell short of the $61.7 billion expectation, indicating the impact of market demand fluctuations on performance.
- Adjusted Earnings Per Share: The company posted adjusted EPS of $3.17, surpassing the consensus estimate of $2.79, demonstrating strong profitability despite overall sales missing expectations across all segments.
- Free Cash Flow Performance: Free cash flow reached $3.3 billion, three times the Street's consensus estimate, showcasing the company's robust cash management capabilities, although challenges persist in the Global Medical Products and Distribution segment.
- Full-Year Earnings Outlook Raised: Cardinal raised its adjusted earnings outlook for fiscal year 2026 to $10.70 to $10.80 per share, ahead of the Street estimate of $10.31, although only 13 cents of the increase is attributed to operational performance, reflecting cautious market sentiment regarding future growth.
See More
S&P 500 Hits Record Highs, AI Stocks Shine
- S&P 500 Performance: The S&P 500 is on track to close at another record high after its best month since November 2020, indicating strong market confidence in economic recovery as of Friday.
- AI Stock Surge: AI-related stocks like Arm, Broadcom, and Alphabet saw significant gains in April, with Arm surging nearly 40% and others rising over 30%, reflecting sustained investor enthusiasm and strong demand for AI technologies.
- Impact of Rising Memory Prices: Companies like Meta and Microsoft have raised their capital expenditure guidance due to surging memory prices, with Microsoft projecting $190 billion in capex for 2026, of which $25 billion is attributed to rising component costs, highlighting the tightness in the memory market.
- Multi-Year Supply Agreements: SanDisk has signed five multi-year supply agreements valued at over $11 billion, ensuring stable demand for its customers and indicating strong bargaining power for memory manufacturers, which could impact future sales and margins.
See More
Cardinal Health Upgraded to Overweight Rating
- Rating Upgrade: Cardinal Health has received an upgrade to an overweight rating, indicating a positive outlook from the market regarding its future performance, which may attract more investor interest.
- Price Target Analysis: The average price target set by analysts is $249.07, reflecting a bullish sentiment towards the company's stock, and if achieved, it could yield significant returns for investors.
- Market Reaction: The rating upgrade could lead to a short-term increase in stock price, boosting investor confidence and enhancing the company's market position within the healthcare sector.
- Investor Strategy: With the rating improvement, investors may reassess their portfolios and consider increasing their holdings in Cardinal Health to capitalize on potential higher returns.
See More
Apple's Strong Earnings Propel Stock Market Higher
- Apple's Earnings Surprise: Apple reported a projected revenue increase of 14% to 17% for the June quarter, significantly exceeding the Street's expectation of 9%, which solidifies its leadership position in the tech industry.
- Record Services Revenue: The company's services revenue reached an all-time high of $30.97 billion, up 16% year-over-year, indicating strong growth potential in its digital services segment and expected to drive future revenue growth.
- Positive Market Reaction: Apple's stock rose by 3.5%, with Wells Fargo raising its price target from $300 to $310, reflecting market optimism regarding its future performance.
- Memory Price Concerns: Despite Sandisk's earnings beating expectations, its shares fell 5%, highlighting market concerns over rising memory chip prices, which could impact overall industry profitability.
See More
Analysis of Cardinal Health's Quarterly Results
- Overreaction in Market: Cardinal Health's stock fell 4.9% following Thursday's earnings report, which analysts believe was an overreaction; based on the company's long track record of double-digit earnings-per-share growth, investors should consider buying on Friday.
- Clear Strategic Direction: Despite the $184 million goodwill impairment charge mentioned in the report causing some noise, CEO Jason Hollar reaffirmed that the strategy for this business line remains unchanged, demonstrating the company's confidence in future growth.
- Attractive Valuation: Cardinal's shares are currently trading at approximately 16.5 times next year's earnings estimates, down from about 20 times in early March, indicating a potential opportunity for investors as the market reassesses its valuation.
- Analyst Consensus Optimistic: Several Wall Street analysts believe the market overreacted, with Jefferies and Leerink Partners stating that the investment thesis for Cardinal remains intact, and in a market where healthcare stocks are out of favor, Cardinal is viewed as a quality asset worth investing in.
See More
Cardinal Health Reports Strong Q3 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Cardinal Health's total revenue increased by 11% to $61 billion in Q3, primarily driven by strong performance in its Pharmaceutical and Specialty Solutions business, demonstrating the company's competitive edge and sustained growth potential in the market.
- Improved Profitability: Enterprise operating earnings rose by 18% to $956 million, reflecting the company's successful positioning in higher-margin businesses, which also provides funding for future investments and expansions.
- Optimistic Outlook: Management raised the fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80 and adjusted free cash flow guidance to a range of $3.3 billion to $3.7 billion, indicating strong confidence in future performance and proactive market strategies.
- Strong Specialty Business Growth: The Specialty segment saw over 20% revenue growth in Q3, with expectations for Specialty revenue to exceed $50 billion in fiscal 2026, highlighting the company's advantageous position in rapidly growing niche markets.
See More
Cardinal Health Reports Mixed Quarterly Results, Shares Decline
- Quarterly Revenue Growth: Cardinal Health reported an 11% year-over-year revenue increase to $60.94 billion for the quarter ending March 31, although it fell short of the $61.7 billion expectation, indicating the impact of market demand fluctuations on performance.
- Adjusted Earnings Per Share: The company posted adjusted EPS of $3.17, surpassing the consensus estimate of $2.79, demonstrating strong profitability despite overall sales missing expectations across all segments.
- Free Cash Flow Performance: Free cash flow reached $3.3 billion, three times the Street's consensus estimate, showcasing the company's robust cash management capabilities, although challenges persist in the Global Medical Products and Distribution segment.
- Full-Year Earnings Outlook Raised: Cardinal raised its adjusted earnings outlook for fiscal year 2026 to $10.70 to $10.80 per share, ahead of the Street estimate of $10.31, although only 13 cents of the increase is attributed to operational performance, reflecting cautious market sentiment regarding future growth.
See More
S&P 500 Hits Record Highs, AI Stocks Shine
- S&P 500 Performance: The S&P 500 is on track to close at another record high after its best month since November 2020, indicating strong market confidence in economic recovery as of Friday.
- AI Stock Surge: AI-related stocks like Arm, Broadcom, and Alphabet saw significant gains in April, with Arm surging nearly 40% and others rising over 30%, reflecting sustained investor enthusiasm and strong demand for AI technologies.
- Impact of Rising Memory Prices: Companies like Meta and Microsoft have raised their capital expenditure guidance due to surging memory prices, with Microsoft projecting $190 billion in capex for 2026, of which $25 billion is attributed to rising component costs, highlighting the tightness in the memory market.
- Multi-Year Supply Agreements: SanDisk has signed five multi-year supply agreements valued at over $11 billion, ensuring stable demand for its customers and indicating strong bargaining power for memory manufacturers, which could impact future sales and margins.
See More
Cardinal Health Upgraded to Overweight Rating
- Rating Upgrade: Cardinal Health has received an upgrade to an overweight rating, indicating a positive outlook from the market regarding its future performance, which may attract more investor interest.
- Price Target Analysis: The average price target set by analysts is $249.07, reflecting a bullish sentiment towards the company's stock, and if achieved, it could yield significant returns for investors.
- Market Reaction: The rating upgrade could lead to a short-term increase in stock price, boosting investor confidence and enhancing the company's market position within the healthcare sector.
- Investor Strategy: With the rating improvement, investors may reassess their portfolios and consider increasing their holdings in Cardinal Health to capitalize on potential higher returns.
See More
Apple's Strong Earnings Propel Stock Market Higher
- Apple's Earnings Surprise: Apple reported a projected revenue increase of 14% to 17% for the June quarter, significantly exceeding the Street's expectation of 9%, which solidifies its leadership position in the tech industry.
- Record Services Revenue: The company's services revenue reached an all-time high of $30.97 billion, up 16% year-over-year, indicating strong growth potential in its digital services segment and expected to drive future revenue growth.
- Positive Market Reaction: Apple's stock rose by 3.5%, with Wells Fargo raising its price target from $300 to $310, reflecting market optimism regarding its future performance.
- Memory Price Concerns: Despite Sandisk's earnings beating expectations, its shares fell 5%, highlighting market concerns over rising memory chip prices, which could impact overall industry profitability.
See More
Analysis of Cardinal Health's Quarterly Results
- Overreaction in Market: Cardinal Health's stock fell 4.9% following Thursday's earnings report, which analysts believe was an overreaction; based on the company's long track record of double-digit earnings-per-share growth, investors should consider buying on Friday.
- Clear Strategic Direction: Despite the $184 million goodwill impairment charge mentioned in the report causing some noise, CEO Jason Hollar reaffirmed that the strategy for this business line remains unchanged, demonstrating the company's confidence in future growth.
- Attractive Valuation: Cardinal's shares are currently trading at approximately 16.5 times next year's earnings estimates, down from about 20 times in early March, indicating a potential opportunity for investors as the market reassesses its valuation.
- Analyst Consensus Optimistic: Several Wall Street analysts believe the market overreacted, with Jefferies and Leerink Partners stating that the investment thesis for Cardinal remains intact, and in a market where healthcare stocks are out of favor, Cardinal is viewed as a quality asset worth investing in.
See More
Cardinal Health Reports Strong Q3 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Cardinal Health's total revenue increased by 11% to $61 billion in Q3, primarily driven by strong performance in its Pharmaceutical and Specialty Solutions business, demonstrating the company's competitive edge and sustained growth potential in the market.
- Improved Profitability: Enterprise operating earnings rose by 18% to $956 million, reflecting the company's successful positioning in higher-margin businesses, which also provides funding for future investments and expansions.
- Optimistic Outlook: Management raised the fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80 and adjusted free cash flow guidance to a range of $3.3 billion to $3.7 billion, indicating strong confidence in future performance and proactive market strategies.
- Strong Specialty Business Growth: The Specialty segment saw over 20% revenue growth in Q3, with expectations for Specialty revenue to exceed $50 billion in fiscal 2026, highlighting the company's advantageous position in rapidly growing niche markets.
See More
